Tigecycline for E. coli Infections
Tigecycline is appropriate for treating E. coli infections in specific clinical contexts, particularly complicated intra-abdominal infections (cIAI) and complicated skin/soft tissue infections (cSSSI), but should NOT be used for urinary tract infections or bloodstream infections due to inadequate drug concentrations at these sites. 1
FDA-Approved Indications for E. coli
Tigecycline is FDA-approved for E. coli in the following scenarios 1:
- Complicated intra-abdominal infections (cIAI) - caused by susceptible E. coli isolates
- Complicated skin and skin structure infections (cSSSI) - caused by susceptible E. coli isolates
- NOT approved for: Hospital-acquired pneumonia, ventilator-associated pneumonia, or diabetic foot infections
Recommended Dosing Regimen
Standard adult dosing 1:
- Loading dose: 100 mg IV
- Maintenance: 50 mg IV every 12 hours
- Infusion time: 30-60 minutes
- Duration: 5-14 days for cIAI/cSSSI
Dose adjustments:
- Severe hepatic impairment (Child-Pugh C): Reduce maintenance to 25 mg IV every 12 hours 1
- Renal impairment: No dose adjustment needed 2
Clinical Context Matters
When Tigecycline IS Appropriate:
For multidrug-resistant E. coli 3:
- Carbapenem-resistant Enterobacterales (CRE) including E. coli: Tigecycline 100 mg loading, then 50 mg IV q12h is recommended for cIAI 3
- ESBL-producing E. coli: Tigecycline demonstrates excellent in vitro activity with MIC50/MIC90 of 0.5/0.5 µg/mL, well below achievable concentrations 4
- Community-acquired cIAI: Tigecycline is listed as an acceptable single-agent option for mild-to-moderate infections 5
When Tigecycline Should NOT Be Used:
Bloodstream infections: Tigecycline achieves low serum concentrations due to large volume of distribution, making it unsuitable for bacteremia 3, 1. The FDA label explicitly warns of increased all-cause mortality in clinical trials 1.
Urinary tract infections: Despite case reports showing 88.9% favorable response 6, tigecycline is NOT recommended as first-line for UTIs. Urinary concentrations are inadequate for reliable efficacy. Use only when no other susceptible options exist 6.
Hospital-acquired/ventilator-associated pneumonia: FDA specifically contraindicates tigecycline for these indications due to increased mortality and decreased efficacy 1.
Pharmacokinetic Considerations
Target exposure for cIAI: AUC/MIC ratio ≥6.96 predicts microbiological and clinical success 7. The standard 50 mg q12h regimen achieves this target for most E. coli isolates.
Higher doses may be needed for:
- Patients with higher BMI (increased clearance) 8
- Infections requiring AUC/MIC >17.9 (though this target is for skin infections) 8
- MIC values approaching resistance breakpoints 2
Critical Warnings
Black Box Warning: Meta-analysis showed 0.6% increased all-cause mortality with tigecycline versus comparators 1. Reserve tigecycline for situations when alternative treatments are not suitable.
Common pitfalls to avoid:
- Using tigecycline for E. coli bacteremia - serum levels are too low 3
- Empiric use without considering local resistance patterns - quinolone-resistant E. coli is common in many communities 5
- Using standard doses for severely resistant organisms - may need higher maintenance doses (100 mg q12h) 9
- Monotherapy for severe infections - combination therapy should be considered for critically ill patients 10
Resistance Considerations
While tigecycline maintains excellent activity against ESBL-producing E. coli 4, 11, the 2010 IDSA/SIS guidelines express concern about broad use potentially selecting for resistance 5. Use should be judicious and guided by susceptibility testing when available.
For CRE-associated cIAI, newer agents like ceftazidime-avibactam are preferred when available, with tigecycline as an alternative option 3.